Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Alpesh Amin

Hospital Medicine · UCI

View

Dr. Akua Ampadu

Hospital Medicine · NYP Weill Cornell

View

Dr. Reza Manesh

Hospital Medicine · Greater Los Angeles VA

View

Dr. Michael Calavano

Hospital Medicine · NYP Weill Cornell

View

Dr. Nasim Afsar

Hospital Medicine

View

Dr. Sara Murray

Hospital Medicine · Johns Hopkins Medicine

View

Dr. Robert Korom

Hospital Medicine · Penda Health

View

Dr. Sunil Kripalani

Hospital Medicine · VUMC

View

Dr. Ronald Greeno

Hospital Medicine · Society of Hospital Medicine

View

Dr. Moises Auron

Hospital Medicine · Cleveland Clinic

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital.

    May 20, 2026DOI: 10.1093/cid/ciaf390Journal ArticleCID

    Written by: Sergio Alvarez MulettSofia Molina GarciaOmar Abu SalehMatthew J WolfAmanda A RodningNancy L WengenackAndrew P NorganRobin Patel

    Find these authors on Roon

    SA
    Dr. Sergio Alvarez-Mulett
    Hospital Medicine

    Summary

    BACKGROUND: Central nervous system (CNS) infections are significant causes of morbidity and mortality, especially when diagnosis is delayed. Traditional cerebrospinal fluid diagnostic methods for CNS infections have limited sensitivity. Metagenomic next-generation sequencing of cerebrospinal fluid (MSCSF) is a newer diagnostic tool capable of detecting a broad range of pathogens in a single assay.METHODS: This retrospective cohort study evaluated the first-year experience with MSCSF at Mayo Clinic. A total of 422 tests performed during calendar year 2024 on adult patients at Mayo Clinic facilities and those tested through Mayo Clinic Laboratories were analyzed, with a subcohort analysis of the 210 Mayo Clinic patients performed to define patient characteristics associated with positive results and clinical outcomes.RESULTS: The sensitivity of MSCSF for detecting neuroinfection in the subcohort was 64%, with 43% of confirmed neuroinfections diagnosed by MSCSF only. Subjects who were immunosuppressed (odds ratio P = .008) and those with a high pretest probability of CNS infection (OR: 20.1, P < .001) were more likely to have positive results. Also, those who tested positive were more likely to die within the ensuing 30 days than those who tested negative (OR: 5.2, P = .001).CONCLUSIONS: MSCSF can be a valuable tool for diagnosing CNS infection but should not be used indiscriminately. It appears to be most beneficial when there is a high clinical suspicion of CNS infection and conventional diagnostics, and available molecular tests, yield negative results. Its integration into clinical practice should be guided by diagnostic stewardship to maximize cost-effectiveness and clinical utility.
    SADr. Sergio Alvarez-Mulett

    Dr. Sergio Alvarez-Mulett

    Internal Medicine · Hospital Medicine
    sergio